<code id='516AB5A07A'></code><style id='516AB5A07A'></style>
    • <acronym id='516AB5A07A'></acronym>
      <center id='516AB5A07A'><center id='516AB5A07A'><tfoot id='516AB5A07A'></tfoot></center><abbr id='516AB5A07A'><dir id='516AB5A07A'><tfoot id='516AB5A07A'></tfoot><noframes id='516AB5A07A'>

    • <optgroup id='516AB5A07A'><strike id='516AB5A07A'><sup id='516AB5A07A'></sup></strike><code id='516AB5A07A'></code></optgroup>
        1. <b id='516AB5A07A'><label id='516AB5A07A'><select id='516AB5A07A'><dt id='516AB5A07A'><span id='516AB5A07A'></span></dt></select></label></b><u id='516AB5A07A'></u>
          <i id='516AB5A07A'><strike id='516AB5A07A'><tt id='516AB5A07A'><pre id='516AB5A07A'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:hotspot    Page View:1336
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In